桂林三金药业股份有限公司 2025 年半年度财务报告 桂林三金药业股份有限公司 2025年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：桂林三金药业股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 1,048,460,795.40 | 1,049,601,773.61 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 611,203,698.67 | 626,146,300.49 | | 衍生金融资产 | | | | 应收票据 | | | | 应收账款 | 244,048,333.67 | 86,439,552.21 | | 应收款项融资 | 100,719,501.50 | 440,862,988.56 | | 预付款项 | 24,830,804.81 | 19,118,609.85 | | 应收保费 | | | | 应收分 ...

桂林三金药业股份有限公司 2025 年半年度报告全文 桂林三金药业股份有限公司 2025 年半年度报告 2025 年 8 月 1 桂林三金药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人邹洵、主管会计工作负责人谢元钢及会计机构负责人(会计主 管人员)曾杰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异。 可能存在行业政策变动、公司产品价格下降、产品相对集中、市场竞争 加剧、原辅材料价格波动、研发创新等风险，敬请广大投资者注意投资风险。 详情请见本报告"第三节 十、公司面临的风险和应对措施"中相关描述，请 投资者注意阅读。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 4 桂林三金药业股份有限公司 2 ...

证券日报网讯 桂林三金8月27日在互动平台回答投资者提问时表示，公司三金片和西瓜霜在海外很多市 场都有销售，如东欧的塞尔维亚、美洲的美国和加拿大、大洋洲的澳大利亚、东南亚地区大部分国家 等。市场推广与建设需要一定的时间积累，公司将利用产品在海外华人市场中的口碑与品牌优势，逐步 向当地人市场渗透，以实现销量的增长。 （编辑 王雪儿） ...

针对上述提问，桂林三金回应称："您好，公司三金片和西瓜霜在海外很多市场都有销售，如东欧的塞 尔维亚、美洲的美国和加拿大、大洋洲的澳大利亚、东南亚地区大部分国家等。市场推广与建设需要一 定的时间积累，公司将利用产品在海外华人市场中的口碑与品牌优势，逐步向当地人市场渗透，以实现 销量的增长。谢谢。"责任编辑：栎树 金融界8月27日消息，有投资者在互动平台向桂林三金提问："请问公司目前是否有海外营收？" ...

Group 1 - The stock price of Guilin Sanjin reached 15.68 yuan as of August 12, 2025, reflecting a 0.90% increase from the previous trading day [1] - The trading volume on that day was 194 million yuan, with a turnover rate of 2.21%, and the total market capitalization stood at 9.213 billion yuan [1] - Guilin Sanjin operates in the traditional Chinese medicine manufacturing industry, focusing on the research, production, and sales of traditional Chinese medicine and chemical drugs [1] Group 2 - The company's product portfolio includes well-known medications such as Sanjin Pian and Xigua Shuang series, and it is also involved in flu prevention and monoclonal antibody drugs [1] - In response to investor inquiries, the company stated it will closely monitor changes in national policies, enhance risk management, and adjust product structure and marketing strategies as needed [1] - The company is improving its online terminal agreement client layout in the OTC channel and increasing investment in online operations while enhancing brand influence through comprehensive online and offline promotions [1] Group 3 - On August 12, the net outflow of main funds was 1.1881 million yuan, with a cumulative net outflow of 73.1303 million yuan over the past five trading days [1]

Core Viewpoint - The company will closely monitor and actively respond to changes in national policies, enhancing its analysis of significant and sensitive industry information to adapt to trends in industry development [1] Group 1: Company Strategy - The company emphasizes the importance of risk management and will strengthen its internal management practices, including production, quality, and safety [1] - The company plans to adjust its product structure and marketing strategies in response to policy impacts [1] - The company aims to improve its overall competitiveness by establishing comprehensive regulations and enhancing internal management systems [1]

Group 1 - The company is enhancing its online sales capabilities by improving the layout of online terminal agreements and increasing resource allocation for online operations [1] - The company is actively promoting its brand through comprehensive online and offline marketing activities, which effectively increases brand exposure [1]

Market Performance - The three major A-share indices closed higher, with the Shanghai Composite Index up by 0.45%, the Shenzhen Component Index up by 0.64%, and the ChiNext Index up by 0.66% [1] - The Northbound 50 Index increased by 1.58%, and the total trading volume in the Shanghai and Shenzhen markets reached 1.7591 trillion yuan, an increase of 143.3 billion yuan compared to the previous day [1] - Over 3,300 stocks in the two markets experienced gains [1] Sector Performance - The PEEK materials, military equipment, and humanoid robot sectors saw significant gains [1] - PEEK materials showed strong performance, with companies like Zhongxin Fluorine Materials (002915) hitting the daily limit, and others such as Kaisheng New Materials (301069) and Xinhang New Materials (301076) also reaching the daily limit [1] - The military equipment sector continued to strengthen, with companies like Guorui Technology (300600) and Jiekang Equipment (300875) hitting the daily limit [1] - The humanoid robot sector also performed well, with Huami New Materials reaching the daily limit and several other companies like Haichang New Materials (300885) also hitting the daily limit [1] - Conversely, the pharmaceutical sector experienced a collective adjustment, with Qizheng Tibetan Medicine (002287) dropping over 9% and Guilin Sanjin (002275) declining nearly 7% [1]

Group 1 - The company, Guilin Sanjin (002275), reported that as of July 31, 2025, the total number of shareholders is 18,864 [1]

Group 1 - On August 5, Guilin Sanjin executed a block trade of 1 million shares, with a transaction value of 17.38 million yuan, accounting for 4% of the total trading volume for the day [1][2] - The transaction price was 17.38 yuan, which was in line with the market closing price of 17.38 yuan [1][2]